Endocyte, Inc. (ECYT)
-NasdaqGS 14.02 0.00(0.00%) May 24, 4:00PM EDT
| Prev Close: | 14.02 |
|---|
| Open: | 13.97 |
|---|
| Bid: | 10.88 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 16.83 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 13.80 - 14.15 |
|---|
| 52wk Range: | 6.23 - 15.36 |
|---|
| Volume: | 137,604 |
|---|
| Avg Vol (3m): | 293,959 |
|---|
| Market Cap: | 504.33M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.32 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Merck Stock Is a Good Investment (According to Merck)at Motley Fool(Fri, May 24)
- ENDOCYTE INC FinancialsEDGAR Online Financials(Fri, May 17)
- ENDOCYTE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Endocyte Appoints Scot L. Harper, Ph.D., as Vice President of Clinical OperationsGlobeNewswire(Tue, May 7)
- Wider-than-Expected Loss at EndocyteZacks(Mon, May 6)
- Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Tripleat Seeking Alpha(Fri, May 3)
- Endocyte's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
- Endocyte Reports First Quarter 2013 Financial Results and Business UpdateGlobeNewswire(Thu, May 2)
- ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 2)
- Q1 2013 Endocyte Earnings Release - Time Not SuppliedCCBN(Thu, May 2)
- Expert Analyst Ian Somaiya Discusses the Decline in European Drug Pricing with The Wall Street Transcript; Models a 1% to 2% Annual Decline in Price for Companies That Sell OverseasWall Street Transcript(Tue, Apr 30)
- ENDOCYTE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Fri, Apr 26)
- Clinical Study Shows Involvement of Activated Macrophages in Osteoarthritis, Identified by Endocyte's EtarfolatideGlobeNewswire(Thu, Apr 25)
- 1 Potential Roadblock for the Merck Stock Run-upat Motley Fool(Tue, Apr 23)
- Endocyte, Inc. Announces Annual Stockholders' MeetingGlobeNewswire(Mon, Apr 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.25 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.32 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imagin...
View More 
0.06%